U.S. Markets closed

HCW Biologics Inc. (HCWB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6300-0.1700 (-6.07%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8000
Bid2.5500 x 1000
Ask2.8000 x 800
Day's Range2.5610 - 2.8000
52 Week Range2.3600 - 7.7750
Avg. Volume3,054,663
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

    MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021. “The third quarter of 2021 and recent weeks were an impo

  • Benzinga

    Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results

    Toward the end of trading Thursday, the Dow traded up 0.45% to 35,651.09 while the NASDAQ rose 1.21% to 15,420.51. The S&P also rose, gaining 0.83% to 4,589.40. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 46,597,000 cases with around 761,850 deaths. India confirmed a total of at least 34,231,800 cases and 456,410 deaths, while Brazil reported over 21,766,160 COVID-19 cases with 606,720 deaths. In total, there were at least 245,904,790 cases

  • Benzinga

    Why Did HCW Biologics Shares More Than Double Today?

    Recently listed HCW Biologics Inc (NASDAQ: HCWB) shares almost doubled during premarket Thursday, after FDA signed off Phase 1b trial of its lead candidate in pancreatic cancer. The drug candidate, HCW9218, is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity while simultaneously blocking unwanted immunosuppressive activities. In preclinical studies, HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel agai